长江商报消息 海油工程（600583.SH）抛出收购计划。 近日，海油工程公告称，公司的全资子公司海洋石油工程（珠海）有限公司（以下简称"海工珠海"）拟 8.59亿元收购中海福陆重工有限公司（以下简称"中海福陆"）全部49%股权。交易完成后，海工珠海将 持有中海福陆100%股权。 长江商报记者注意到，该交易价格显著低于评估值。目前，中海福陆盈利良好，其2024年度实现净利润 5080.97万元；2025年前三季度实现净利润9091万元，已经超过2024年全年。 海油工程称，此举旨在实现公司战略规划与业务布局，持续推进深水及新能源工程装备领域的差异化能 力建设，同时加强公司对中海福陆的管控力度，优化其股权结构，提升经营管理与决策效率。 据了解，中海福陆成立于2016年，注册资本约10亿美元，主营业务为项目总承包、油气建设项目的设 计、海上石油项目建设及其他海上项目建设等。 财务信息显示，截至2025年9月30日，中海福陆净资产为40.46亿元。其2024年度实现营业收入22.76亿 元，净利润5080.97万元；2025年前三季度实现营业收入15亿元，净利润9091万元，业绩稳步增长。其 中，2025年前三季度 ...

Core Insights - Lunan Pharmaceutical Group has been recognized as the top company in the "Top 100 Innovative Private Enterprises" list for four consecutive years, showcasing its strong commitment to innovation in the pharmaceutical industry [1] - The company has accumulated over 2,800 patent authorizations and maintained a research and development investment intensity of over 10% for five consecutive years, establishing a robust innovation moat [1] Group 1: Innovation and Research - Lunan Pharmaceutical initiated a national key laboratory restructuring plan to integrate traditional Chinese medicine with modern pharmaceutical practices, overcoming industry challenges [2] - The company successfully developed a domestic culture medium that significantly reduced costs from 150 RMB per liter to 10 RMB, enabling the launch of a CD20 monoclonal antibody injection and breaking a 20-year foreign monopoly [3] - Lunan has established a research network with five national and eleven provincial platforms, collaborating with over 100 top global universities, resulting in an average of one new patent every three days [3] Group 2: Talent Strategy - The company employs a dual strategy of attracting global talent while cultivating local talent, ensuring a sustainable talent ecosystem [4] - The "Shennong Plan" and "Excellent Engineer Class" are key initiatives for recruiting top-tier talent, with competitive compensation packages and comprehensive research support [5] - The average age of the R&D team is 32, reflecting a youthful and dynamic workforce capable of handling over 40 clinical studies for new drugs [6] Group 3: Strategic Collaboration and Industry Impact - Lunan's innovation strategy has evolved from individual technological breakthroughs to a comprehensive restructuring of the industry chain, exemplified by the successful launch of the rituximab project [7] - The company has shared its breakthroughs in culture medium technology with eight local pharmaceutical companies, leading to an 18% reduction in overall production costs in Shandong [7] - Lunan Pharmaceutical has submitted over 40 active pharmaceutical ingredient registration applications in the U.S. and has 72 formulations approved in 129 countries, positioning its products prominently in international markets [8]